![]() |
|
|
Vol. 54, Issue 2, 305-312, August 1998
and µ Are Closely
Related Calpain-Sensitive Proteins
Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94143-0446
| |
Summary |
|---|
|
|
|---|
The neuronal nitric oxide synthase isoform nNOSµ, which is expressed
in striated muscle, differs from nNOS
, the major brain isoform, by
the insertion of 34 amino acid residues between the calmodulin- and
flavin-binding domains [J Biol Chem
271:11204-11208 (1996)]. We show here that recombinant,
purified nNOSµ, despite the peptide insertion, has the same
spectroscopic properties, L-arginine
kcat and
Km values, optimal pH, and
calmodulin binding affinity constant as nNOS
. However, nNOSµ
consumes NADPH and reduces cytochrome c at approximately
half the rate of nNOS
. The rates of degradation of the two proteins
by rat brain and muscle homogenates show that nNOSµ is degraded more
slowly than nNOS
. The in vitro half-lives of nNOS
and nNOSµ are 12 and 50 min, respectively, and calpain is important
for this degradation. These short in vitro half-lives
suggest that the nNOS isoforms are susceptible to rapid degradation in
vivo. The elevated (20-fold) levels of calpain in diseased muscle
tissue in Duchenne muscular dystrophy, and the hydrolytic sensitivity
of both nNOSµ and nNOS
to this enzyme, may contribute to the
deficiency of nNOS activity in the diseased tissue.
| |
Introduction |
|---|
|
|
|---|
NOS
enzymes catalyze the NADPH- and O2-dependent
conversion of L-Arg to nitric oxide (·NO) and
citrulline (Iyengar et al., 1987
; Kwon et al.,
1990
). This transformation involves two successive oxidations of the L-Arg guanidino function: the first yields
N
-hydroxy-L-Arg and the
second converts this intermediate into the final reaction products
(Stuehr et al., 1991
). The NOS isoforms are large,
multidomain polypeptides that are catalytically active as homodimers
(Schmidt et al., 1991
). Each of the subunits of the dimer
binds heme (iron protoporphyrin IX regardless of the valence and
ligation states), FAD, FMN and tetrahydrobiopterin (H4B) as prosthetic groups. The heme is
incorporated into a hemoprotein domain in which a cysteine residue
provides the fifth ligand to the iron atom (McMillan et al.,
1992
; Stuehr and Ikeda-Saito, 1992
; White and Marletta, 1992
), and the
two flavins are part of a reductase domain with strong sequence
similarity to cytochrome P450 reductase (Bredt et al.,
1991
). H4B binds to the heme domain but its role
remains obscure (Mayer and Werner, 1995
). In addition to the above
cofactors, the oxidation of L-Arg to ·NO and
citrulline requires the binding of CaM to a CaM-binding motif
connecting the heme and flavin domains (Bredt and Snyder, 1990
; Zhang
and Vogel, 1994
).
The products of at least three distinct NOS genes have been identified
in mammals. The neuronal (nNOS, NOS-I) and endothelial (eNOS, NOS-III)
isoforms are constitutively expressed in the brain and endothelial
cells, respectively (Bredt and Snyder, 1990
; Pollock et al.,
1991
). The activities of these two isoforms are regulated by the
Ca2+-concentration because they bind CaM in a
Ca2+-dependent manner. The macrophage (iNOS,
NOS-II) isoform is not constitutively expressed but its expression is
induced by cytokines (Hevel et al., 1991
). CaM is tightly
bound to iNOS in an essentially Ca2+-independent
manner (Cho et al., 1992
), so the enzyme activity is
controlled by its rate of expression rather than by the
Ca2+-concentration.
The neuronal enzyme exists in different isoforms because of alternative
splicing of the nNOS mRNA. The principal isoform in brain is nNOS
(Eliasson et al., 1997
), but studies of mice with targeted
deletions of exon 2 have led to the demonstration that two minor
isoforms, nNOS
and nNOS
, that do not contain exon 2 account for
~5% of the NOS activity in the brain (Huang et al., 1993
;
Brenman et al., 1996
; Eliasson et al., 1997
).
Another isoform, nNOSµ, was recently found to be expressed as the
single nNOS isoform in rat skeletal muscle (Magee et al.,
1996
; Silvagno et al., 1996
). This novel isoform is slightly
larger than the neuronal nNOS
because of an alternative splicing
that inserts a 34 amino acid peptide into the protein sequence between
the CaM- and FMN-binding domains of the protein. Preliminary studies
with partially purified enzyme from COS cells heterologously expressing
nNOSµ suggest that the kinetics and CaM binding affinities of nNOSµ
are similar to those of nNOS
(Silvagno et al., 1996
).
We report here heterologous expression of nNOSµ in Escherichia
coli and purification and characterization of the protein. The
results establish that the 34-amino-acid insert has measurable but
small effects on the in vitro catalytic activities of the enzyme. Comparison of the degradation of recombinant nNOS
and nNOSµ in incubations with brain and muscle homogenates shows that nNOS
is degraded somewhat more rapidly than nNOSµ. More
importantly, these studies reveal that both proteins have very short
half-lives because of rapid digestion by calpain, a phenomenon that may
be relevant to the Ca2+-dependent regulation of
NOS activity and its defect in Duchenne muscular dystrophy.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
The expression and purification of nNOS
was
carried out as previously reported (Gerber and Ortiz de Montellano,
1995
). Human CaM was expressed in E. coli and was purified
by phenyl Sepharose (Pharmacia, Piscataway, NJ) chromatography
as previously reported (Rhyner et al., 1992
).
Aurintricarboxylic acid and L-Arg were from Aldrich
(Milwaukee, WI), calpain and the calpain inhibitor peptide from Sigma
(St. Louis, MO), and H4B was from Alexis
Biochemicals (San Diego, CA).
L-[3H]Arg was obtained from
Amersham (Arlington Heights, IL). Bradford protein assay kits were from
Bio-Rad (Hercules, CA). Restriction enzymes were from New England
Biolabs (Beverly, MA). DNA purification kits were purchased from QIAGEN
(Chatsworth, CA).
Expression of nNOSµ in E. coli.
Previous
studies in this laboratory have demonstrated that the pCWori vector can
be used to express catalytically active nNOS
in E. coli
(Gerber and Ortiz de Montellano, 1995
). The nNOSµ cDNA was provided
by David Bredt and Houhui Xia (University of California, San Francisco,
CA) (Silvagno et al., 1996
). Because nNOSµ originates from an alternative splicing of the nNOS mRNA, the insert coding for
the 34 amino acids is found in a BlpI-BsmI
fragment of the nNOSµ cDNA that is absent in the equivalent
BlpI-BsmI fragment of the nNOS
cDNA. The
BlpI-BsmI fragment of the nNOSµ cDNA was therefore incorporated into the pCWori-nNOS plasmid from which the
endogenous BlpI-BsmI fragment had been excised.
Expression and purification of nNOSµ was carried out exactly as
described previously for the preparation of nNOS
(Gerber and Ortiz
de Montellano, 1995
).
Enzyme assays.
The activities of the protein preparations
were determined by measuring either the production of ·NO, using
the conversion of HbO2 to Met-Hb, or the
conversion of L-[3H]Arg to
L-[3H]citrulline at 25° (Hevel
and Marletta, 1994
). The reduction of cytochrome c by the
two nNOS forms was assayed at 25° in a 500-µl volume using a
previously described method (Rodriguez-Crespo et al., 1996
).
When indicated, the assay contained CaM in a CaM/NOS molar ratio of
three. NADPH oxidation was quantified spectrophotometrically at 340 nm
using the extinction coefficient
340 = 6200 M
1 cm
1. The
cuvettes held 500 µl of 50 mM HEPES buffer, pH 7.4, containing 2.5% glycerol, 100 µM NADPH, 10 µM H4B, 200 µM
dithiothreitol, 63 units of catalase, 1 mM
Ca2+, 5 µM FAD, and 5 µM FMN. For each rate determination, five different NOS
concentrations were used and the CaM concentration was varied to
preserve the CaM/NOS ratio of three.
Incubation with cell homogenate fractions.
A 0.5-g sample of
Sprague-Dawley rat brain or leg muscle was homogenized in 5 ml of 25 mM Tris buffer, pH 7. The homogenate was centrifuged 10 min
at 15,000 × g. The supernatant and the pellet were
separated and the pellet was resuspended in 5 ml of the same Tris
buffer. To 5 ml of supernatant or resuspended pellet were added 2 mM ATP (final concentration), 10 mM
phosphocreatine, 40 µg/ml phosphocreatine kinase, 10 mM
MgCl2, and 10 mM
CaCl2. Incubations were carried out at 25°. The
background activities in the supernatant and the resuspended pellet
were determined immediately after these additions and 45 min later. The
supernatant and the resuspended pellet were then separated into two
equal volumes of ~2 ml each and 125 pmol of either nNOS
or nNOSµ
was added to both the supernatant and the resuspended pellet.
Determination of the activity in the cell homogenate.
At
different time points, 250 µl of the solutions from the incubation
mixtures above were added to 250 µl of the
L-[3H]Arg assay reaction mixture
described elsewhere (Hevel and Marletta, 1994
). The slope in cpm/min
was used to calculate the rate of the NOS activity.
pH dependence of the activity.
For this experiment, the
usual HEPES buffer was replaced by a buffer mixture composed of 50 mM ACES buffer, 26 mM Tris, and 26 mM ethanolamine (Ellis and Morrison, 1982
). This mixture of three components has the advantage of maintaining a constant ionic strength over a wide pH range. The pH was adjusted with either HCl or
NaOH to the desired value.
Calpain digestion.
The calpain used in this study was the
80-kDa unit of rabbit skeletal muscle m-calpain purchased from Sigma.
For these studies, a 50-µl final volume of 50 mM Tris
buffer, pH 7.5, containing 90 pmol of nNOS
, 2 pmol of calpain (or
none in control experiments), and 2 mM
CaCl2 was used. The digestion, carried out at
37°, was stopped at different time points by immersion in boiling
water for 1 min. Electrophoresis was done on 8% polyacrylamide gels with a tricine buffer. Western blotting was done using a monoclonal antibody raised against the nNOS reductase domain (Transduction Laboratories, Lexington, KY).
Calpain digestion of endogenous nNOS in brain homogenate. A 0.5-g sample of brain was homogenized in 5 ml of 25 mM Tris buffer, pH 7. To this mixture were added 2 mM ATP (final concentration), 10 mM phosphocreatine, 40 µg/ml phosphocreatine kinase, and 10 mM MgCl2. This mixture was incubated at 25° in the presence or absence of 50 µg/µl of peptidic calpain inhibitor. At different time points, a 500-µl aliquot of each of the incubation mixtures was taken and was boiled. In the absence of the peptidic calpain inhibitor a 1/50 dilution of the boiled aliquot was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting. In the presence of the inhibitor, a 1/10 dilution was used. Western blotting was done with a monoclonal antibody raised against the nNOS reductase domain (Transduction Laboratories, Lexington, KY).
| |
Results |
|---|
|
|
|---|
Expression and Spectroscopic Characterization of nNOSµ
The spectra of the purified recombinant ferric nNOS
and nNOSµ
isoforms are essentially identical (not shown). In the absence of
L-Arg, both forms of the enzyme have an absorbance maximum at 400 nm. The addition of L-Arg to both enzymes causes a
shift of the absorbance maximum from 400 to 394 nm. These results are in agreement with the expected shift in the equilibrium from low spin
to high spin (McMillan and Masters, 1993
).
In Vitro Activity
The insertion of 34 amino acids into the middle of the protein sequence might be expected to influence a number of structural and functional parameters, including the catalytic activity, the absorption spectroscopic properties, the substrate affinity, the degree of coupling of L-Arg oxidation to NADPH consumption, the binding of CaM, and the rate of electron transfer from the flavins to the heme group. We have, therefore, compared the behavior of the two isoforms with respect to these parameters.
CaM binding.
Because the peptide insert is close to the
CaM binding site, the additional 34 amino acids in nNOSµ might alter
its interaction with CaM. To examine this possibility, the rate of
oxidation of L-[3H]Arg to
citrulline at a constant concentration of the substrate (15 µM) and NOS (7.5 nM) was monitored as the CaM
concentration was varied. These measurements provide a pseudo-half
saturation constant K1/2. This constant depends
on the nNOS concentration, but if the concentrations of the two nNOS
isoforms are the same, a comparison between them is possible. Very
similar binding affinities are obtained for the two enzymes:
KnNOSµ = 5 ± 2 nM and
KnNOS
= 7 ± 3 nM
(Table 1). These values are comparable to
the value of ~3 nM obtained with nNOSµ expressed in COS
cells (Silvagno et al., 1996
).
|
Coupling of the reaction.
It has been shown that the reaction
of nNOS is uncoupled and that consumption of NADPH in the absence of
L-Arg is larger than in its presence (Abu-Soud et
al., 1994
). As the insert is located near the FMN-binding domain,
it might alter the degree of coupling of the reaction by, for example,
decreasing the consumption of NADPH in the absence of
L-Arg. The NADPH consumption of the two isoforms with and
without L-Arg was therefore compared (Table 1). Both
enzymes consume NADPH in the absence of L-Arg, but the rate
of NADPH consumption by nNOSµ is approximately half that of nNOS
(Table 1). The addition of L-Arg has a similar effect on
the two nNOS isoforms in that the NADPH consumption decreases in both
cases to 66% of the value in the absence of L-Arg.
Reduction of cytochrome c.
Because of the
proximity of the FMN binding site to the 34 amino acid insert, it is
conceivable that intermolecular electron transfer might be altered.
Because CaM is important for this transfer, we measured the rate of
cytochrome c reduction in the absence and presence of a
saturating concentration of CaM (Table 1). Again, the peptide insert
has only a modest influence on this parameter. The rate of reduction of
cytochrome c by nNOSµ is roughly half that for nNOS
,
both in the presence and absence of CaM.
pH dependence of the activity. Although the differences between the two isoforms in the parameters that would seem to be most susceptible to alteration by the peptide insert are relatively small, it is possible that the two isoforms are located in different subcellular compartments. Because various organelles have different internal pH values, it is possible that the two nNOS isoforms have different optimal pH values. We have therefore measured the catalytic rates of the two isoforms at different pH values with a saturating L-Arg concentration (15 µM) at a fixed CaM/NOS molar ratio of three. Fig. 1 shows the pH dependence of the NOS activity, which is low at pH 5 and pH 8. The optimal pH of approximately 6.4 is similar for both NOS isoforms. The kinetic results summarized here were obtained with the oxyhemoglobin assay, but similar experiments in which the conversion of radiolabeled L-Arg to citrulline was assayed yield essentially identical results. The two enzymes thus have the same pH-activity profile.
|
Activity in the Supernatant and Resuspended Pellet
Because the in vitro studies reveal only modest
differences between the two enzymes, the activities of the two isoforms
were examined in brain and leg muscle homogenates to determine if there are tissue-specific interactions that selectively alter the activities. The homogenates were centrifuged and a fixed amount of enzyme was added
to either the supernatant or the pellet as described in Experimental
Procedures. The background activity was measured at two different
times, immediately after separation of the supernatant and resuspension
of the pellet (To) and 45 min after
separation and resuspension of the pellet
(T45). Because the background activity is
much higher at To than at
T45 (Fig. 2),
the enzyme was added to the appropriate cell fraction at
T45. Addition of nNOSµ, which is not
found in the brain, to brain supernatant or pellet gives the same
result as addition of nNOS
. The reciprocal experiment, addition of
nNOS
to the leg muscle supernatant or pellet also yields similar
results to those obtained by addition of nNOSµ (Fig. 2). There do not
seem to be differential tissue effects on the catalytic rates of the
two isoforms.
|
Time Dependence of nNOS Activity
The observation of a decrease in the background activity suggested
that the endogenous NOS (and/or arginase) activity in the cell
homogenate is very time-dependent. To investigate the time dependence
of the NOS activity, we incubated a fixed amount of both recombinant
nNOS
and nNOSµ with the supernatant and pellet fractions from both
the brain and leg muscle homogenates. As before, the enzyme was added
to the mixture after a 45-min preincubation and the activity was
subsequently determined at different time points (Fig.
3). The time-dependent changes in the
activities are different for the two enzymes; nNOSµ is more stable
than nNOS
in incubations with both the brain supernatant and
resuspended pellet. Loss of 50% of the initial nNOS
activity is
observed after 12 and 50 min of incubation with the resuspended pellet and supernatant, respectively, whereas loss of 50% of the nNOSµ activity requires 30 and 67 min, respectively. Incubation of nNOS
in
the muscle homogenate and of nNOSµ in the brain homogenate do not
give rise to behaviors for either of the enzymes that differ from those
seen in their normal environments. In both the brain and leg muscle
homogenates, the two isoforms have very short half-lives, that of
nNOS
being significantly shorter than that of nNOSµ.
|
Digestion of NOS by Calpain
The time dependence of the activity of the nNOS isoforms in the
cell homogenate is consistent with either thermal denaturation or
proteolytic degradation. It has been reported that the catalytic activity of endogenous nNOS in rat brain supernatant decreases in a
time-dependent manner that is not inhibited by the protease inhibitors
phenylmethylsulfonyl fluoride, leupeptin, pepstatin, and soybean
trypsin inhibitor (Mittal and Jadhav, 1994
). This suggested that the
more common serine, aspartate, or thiol proteases might not be
responsible for the observed loss of activity. We therefore examined
the possible involvement of calpain, a
Ca2+-dependent protease (Molinari and Carafoli,
1997
). Calpain is an attractive candidate for this activity because (a)
Barnes and Gomes (1995)
reported that endothelial NOS has a potential
calpain site, (b) Walker et al. (1996)
recently obtained
evidence in cell culture that iNOS may be a substrate for calpain, and
(c) calpain can be both a soluble and membrane bound enzyme (Sato
et al., 1995
; Suzuki et al., 1995
). Calpain is a
Ca2+-activated cysteine protease ubiquitously
distributed in animal cells. A time-dependent study of the digestion of
nNOS
(90 pmol) with the 80-kDa subunit of rabbit skeletal muscle
calpain (2 pmol), monitored by Western blots using a monoclonal
antibody against the reductase domain of nNOS, establishes that calpain
readily digests nNOS (Fig. 4). After 10 min, nNOS
is completely digested to a 79.4-kDa fragment that is
degraded, in turn, to a smaller peptide of ~45 kDa. The results
suggest the presence of at least two calpain-sensitive sites in nNOS,
the most sensitive of which results in complete digestion of nNOS
to
a 79.4-kDa fragment within 10 min of incubation. The size of this first
fragment suggests that the most critical calpain-sensitive site is near
the middle of the protein in the vicinity of the CaM binding domain.
Previous work on the digestion of nNOS by trypsin has shown that this
protease also cleaves the enzyme in the CaM binding domain (Sheta
et al., 1994
)
|
Aurintricarboxylic acid was recently reported by Posner et
al. to be a calpain inhibitor (Posner et al., 1995
). To
further test the role of calpain in the digestion of nNOS
and
nNOSµ by the cell homogenate, we repeated the previous experiment but
in the presence of 500 µM aurintricarboxylic acid (Fig.
5). Aurintricarboxylic acid was added to
the supernatant and the resuspended pellet after the 45 min
preincubation but immediately before nNOS
or nNOSµ was added.
Because the aurintricarboxylic acid might inhibit other proteases or
otherwise alter the stability of the nNOS isoforms, we carried out
similar experiments in the brain pellet with a very specific peptidic
calpain inhibitor (Fig. 6). This peptidic inhibitor derives from the cellular calpain inhibitor calpastatin (Maki
et al., 1989
). The results show that the half-lives of the two isoforms are greatly increased when calpain is inhibited. The
half-life is > 4 hr in the brain pellet in the presence of the
peptidic inhibitor and > 5 hr in the brain and leg muscle homogenates in the presence of aurintricarboxylic acid. Furthermore, these results indicate that loss of the enzymatic activity is not
simply caused by thermal instability of the two proteins, as almost
80% of their activity is preserved after 3 hr under these incubation
conditions. Calpain is thus clearly implicated as a key participant in
the degradation of nNOS
and nNOSµ in the brain and in leg muscle,
respectively.
|
|
Digestion of Endogenous nNOS by Calpain
As already mentioned, brain homogenates have an endogenous NO synthesizing activity when freshly prepared, but this activity decreases with time if the homogenates are incubated with ATP for a period of 30-45 min. To determine if this decrease in the activity of endogenous nNOS is caused by digestion by calpain, freshly prepared brain homogenates were incubated with and without the peptidic calpain inhibitor and the samples were analyzed by Western blotting for loss of immunodetectable nNOS. The results show that the nNOS detected by Western blotting of fresh homogenate is completely degraded after 2 hr incubation at 25° (Fig. 7), in accord with the earlier finding that the NO synthesizing activity is lost in a similar time period (Fig. 2). In contrast, only a modest loss of immunodetectable nNOS is found by Western blotting when the 2 hr incubation is carried out in the presence of the peptidic calpain inhibitor (Fig. 7). These results clearly show that endogenous calpain is the protease that is primarily responsible for the degradation of endogenous nNOS in brain tissue, although the fact that proteolytic peptides similar to those seen in Fig. 4 do not accumulate suggests that the peptides produced by calpain are rapidly digested by other proteases present in the brain tissue.
|
| |
Discussion |
|---|
|
|
|---|
Several isoforms have been identified that result from alternative
splicing of the nNOS gene. Of these nNOS isoforms, nNOS
, nNOS
,
and nNOS
are found in the brain (Huang et al., 1993
;
Brenman et al., 1996
; Eliasson et al., 1997
), but
nNOSµ is found in skeletal muscle (Magee et al., 1996
;
Silvagno et al., 1996
). nNOSµ results from the insertion
of a 34 amino acid peptide between the CaM and FMN domains of the
nNOS
sequence. As shown here, this insertion has measurable but
modest effects on some of the biochemical properties of the enzyme.
The kcat and
Km values for the oxidation of
L-Arg by the two isoforms, as suggested by the
earlier study of the enzyme expressed in COS cells (Silvagno et
al., 1996
), are essentially identical. The presence (or absence)
of the peptide insert therefore does not influence the binding or
oxidation of L-Arg by the two nNOS isoforms.
However, although both nNOS
and nNOSµ consume NADPH at a high rate
in the absence of substrate, the NADPH consumption by nNOSµ is half
of that consumed by nNOS
even though the L-Arg oxidizing activities of the two isoforms are the same (Table 1). This
implies that the 34-amino-acid insert modestly decreases uncoupled
turnover, and consequently the formation of
H2O2, in nNOSµ relative
to nNOS
. These results agree with the finding that the rate of
reduction of cytochrome c by nNOSµ is roughly half of that
by nNOS
, a result that indicates that the flavoprotein domain of
nNOS
gives up electrons more readily to both molecular oxygen and
cytochrome c than the corresponding domain of NOSµ. The
results also indicate that the communication between the reductase and
heme domains in nNOSµ is not altered by the presence of the additional 34 amino acids. The lower electron donating activity of the
reductase domain in nNOSµ does not affect the rate of
L-Arg oxidation, presumably because the intrinsic
electron donating capacity of both isoforms far exceeds the activity
required for the relatively low rate of L-Arg
oxidation (Table 1).
The NOS isoforms are flavin-containing hemoproteins that require the binding of CaM to trigger electron transfer from the reductase to the heme domains of the protein. The binding of CaM also greatly stimulates the reduction of cytochrome c, indicating that CaM binding not only brings about coupling of the reductase and heme domains but causes a change in the flavoprotein domain that enhances its ability to provide electrons. Location of the peptide insert between the CaM binding site and the FMN domain might be expected to alter either the binding of CaM or the electron transfer processes that are controlled by its binding. Our results indicate that the 34 amino acid insert has no influence on either of these parameters (Table 1). Thus, both isoforms have the same affinity for CaM, both require CaM binding for the oxidation of L-Arg, and in both enzymes CaM binding regulates the transfer of electrons to cytochrome c to approximately the same extent. The decreased activity of nNOSµ with respect to NADPH utilization and cytochrome c reduction thus stems from a direct effect of the insert on the reductase domain rather than from an effect mediated by the CaM binding site.
The pH-activity profiles of both nNOS
and nNOSµ exhibit bell
shaped curves with optima at pH ~6.4. For both nNOS isoforms at least
two groups control the pH dependence, one (or more) with a
pKa value of ~5.7 that needs to be
deprotonated for maximum activity, and one (or more) with a
pKa value of ~7 that must be protonated for maximum activity. The similarity of the two pH profiles
means that the 34-amino-acid insert has no influence on the
pKa values of the groups in question.
The peptide insert therefore does not shift the
pKa of the nNOS protein to optimize it for function within a different subcellular environment.
These collective results show that insertion of 34 amino acids between
the nNOS catalytic and reductase domains has only modest effects on the
biochemical behavior of the enzyme and none on its ability to oxidize
L-Arg. The two other known isoforms, nNOS
and nNOS
,
retain only ~80% and ~5%, respectively, of the nNOS
L-Arg oxidizing activity (Brenman et al., 1996
).
The amino-terminal domain of the enzyme deleted in these two isoforms
seems to be important not only for interaction with other proteins but
is also a determinant of the intrinsic NOS activity. In contrast, the
modest catalytic differences between nNOSµ and nNOS
do not seem to
be sufficiently important to provide a rationale for the differential
expression of the two isoforms in brain and skeletal muscle.
The rapid differential degradation of nNOS
and nNOSµ, a key
finding of the present study, is of greater significance than the small
catalytic differences between the two isoforms. The 12 and 30 min
half-lives of nNOS
and nNOSµ, respectively (Fig. 3), when
incubated with the brain pellet, suggest that these nNOS isoforms may
be among the more rapidly degraded proteins in vivo. The
in vivo half-life of ornithine decarboxylase, a rapidly
degraded protein, is ~11 min (Russell and Snyder, 1969
). Digestion of
nNOS
(and nNOSµ-not shown) by calpain (Fig. 4), and inhibition of
activity loss by aurintricarboxylic acid (Fig. 5) and the
calpain-specific inhibitory peptide (Fig. 6) in incubations of the nNOS
isoforms with brain and muscle cellular fractions clearly implicate
calpain as a major protease involved in their rapid degradation. The
key role of calpain in the degradation of nNOS in native tissue is confirmed by the finding that the proteolytic degradation of the endogenous nNOS in brain homogenate, as measured by Western blotting, is prevented by the peptidic calpain inhibitor (Fig. 7). Calpains are
ubiquitous Ca2+-dependent proteases that
selectively cleave a wide variety of substrates. Furthermore, the
earlier report that leupeptin, pepstatin A, phenylmethylsulfonyl
fluoride, and soybean trypsin inhibitor do not prevent the loss of nNOS
activity in rat brain homogenates is consistent with a key role for
calpain versus other proteolytic activities in triggering the
inactivation of the nNOS isoforms (Mittal and Hadhav, 1994
). The
finding that calpain plays a key role in the degradation of nNOS is in
accord with the report that calpain helps to limit the activity of iNOS
in RAW 264.7 cells (Walker et al., 1996
).
Because ·NO is a short-lived free radical, regulation of
signaling occurs largely at the level of ·NO synthesis. Both the
nNOS
and nNOSµ isoforms are rapidly degraded by a
Ca2+-dependent protease; therefore, it is
possible to envision a regulatory effect of protein degradation on
·NO production. Activation of nNOS by Ca2+
would be followed by Ca2+-dependent activation of
calpain, which in turn would contribute to control of the level of
·NO biosynthesis through nNOS catabolism. Proteolytic digestion of the enzyme, like its catalysis-dependent inactivation, provides a
mechanism for preventing the elevated concentrations of ·NO that
are toxic to the cell.
The degradation of nNOS by calpain may play a significant role in
Duchenne muscular dystrophy. It has been reported that nNOS is absent
from the skeletal muscle sarcolemma of Duchenne muscular dystrophy
patients (Brenman et al., 1995
; Chang et al.,
1996
). nNOS is also deficient in the skeletal muscle of young mdx mice, an animal model for Duchenne muscular dystrophy (Chang et
al., 1996
). Furthermore, calpain is overexpressed and activated in the skeletal muscle sarcolemma of deceased mdx mice (Spencer et al., 1995
; Spencer and Tidball, 1996
). Our results suggest that elevated levels of active calpain may accelerate the degradation of
nNOS and thus contribute to the deficiency of nNOS in the skeletal muscle sarcolemma of Duchenne muscular dystrophy patients and mdx mice.
In conclusion, the nNOS
and nNOSµ isoforms are biochemically
closely related but are not identical. Of particular interest is the
demonstration that nNOS is rapidly degraded by calpain, a
Ca2+-dependent protease. This degradation may be
involved in regulation of the cellular concentration of ·NO and
may contribute to the deficiency of nNOS in some muscular disorders.
| |
Acknowledgments |
|---|
We thank David S. Bredt and Houhui Xia (University of California, San Francisco, CA) for the nNOSµ cDNA, Emanuel E. Strehler (Mayo Clinic, Rochester, MN) for the human CaM cDNA, and M. Almira Correia (University of California, San Francisco, CA) for the rat brain and muscle tissue.
| |
Footnotes |
|---|
Received February 16, 1998; Accepted May 1, 1998
This work was supported by National Institutes of Health grant GM25515.
Send reprint requests to: Dr. Paul R. Ortiz de Montellano, Department of Pharmaceutical Chemistry, School of Pharmacy, S-926, University of California, San Francisco, CA 94143-0446. E-mail: ortiz{at}cgl.ucsf.edu
| |
Abbreviations |
|---|
NOS, nitric oxide synthase; H4B, (6R)-5,6,7,8-tetrahydrobiopterin; L-Arg, L-arginine; CaM, calcium-dependent calmodulin; nNOS, neuronal nitric oxide synthase; iNOS, inducible nitric oxide synthase; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; ACES, N-[2-acetamido]-2-aminoethanesulfonic acid.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
G. K. McConell, S. J. Bradley, T. J. Stephens, B. J. Canny, B. A. Kingwell, and R. S. Lee-Young Skeletal muscle nNOS{micro} protein content is increased by exercise training in humans Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R821 - R828. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Chohan, R. B. Singh, N. S. Dhalla, and T. Netticadan L-Arginine administration recovers sarcoplasmic reticulum function in ischemic reperfused hearts by preventing calpain activation Cardiovasc Res, January 1, 2006; 69(1): 152 - 163. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Y. Dunbar, Y. Kamada, G. J. Jenkins, E. R. Lowe, S. S. Billecke, and Y. Osawa Ubiquitination and Degradation of Neuronal Nitric-Oxide Synthase in Vitro: Dimer Stabilization Protects the Enzyme from Proteolysis Mol. Pharmacol., October 1, 2004; 66(4): 964 - 969. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, E. Kodani, J. Wang, S. X. Zhang, H. Takano, X.-L. Tang, and R. Bolli Cardioprotection During the Final Stage of the Late Phase of Ischemic Preconditioning Is Mediated by Neuronal NO Synthase in Concert With Cyclooxygenase-2 Circ. Res., July 9, 2004; 95(1): 84 - 91. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. N. Mungrue and D. S. Bredt nNOS at a glance: implications for brain and brawn J. Cell Sci., June 1, 2004; 117(13): 2627 - 2629. [Full Text] [PDF] |
||||
![]() |
Y. Osawa, E. R. Lowe, A. C. Everett, A. Y. Dunbar, and S. S. Billecke Proteolytic Degradation of Nitric Oxide Synthase: Effect of Inhibitors and Role of hsp90-Based Chaperones J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 493 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Stamler and G. Meissner Physiology of Nitric Oxide in Skeletal Muscle Physiol Rev, January 1, 2001; 81(1): 209 - 237. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Herrmann, V. Straub, M. Blank, C. Kutzick, N. Franke, E. N. Jacob, H.-G. Lenard, S. Kroger, and T. Voit Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy Hum. Mol. Genet., September 1, 2000; 9(15): 2335 - 2340. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. F. Gonzalez-Cadavid, A. L. Burnett, T. R. Magee, C. B. Zeller, D. Vernet, N. Smith, J. Gitter, and J. Rajfer Expression of Penile Neuronal Nitric Oxide Synthase Variants in the Rat and Mouse Penile Nerves Biol Reprod, September 1, 2000; 63(3): 704 - 714. [Abstract] [Full Text] |
||||
![]() |
E. A. Bolan, K. N. Gracy, J. Chan, R. R. Trifiletti, and V. M. Pickel Ultrastructural Localization of Nitrotyrosine within the Caudate-Putamen Nucleus and the Globus Pallidus of Normal Rat Brain J. Neurosci., July 1, 2000; 20(13): 4798 - 4808. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Noguchi, S. Jianmongkol, A. T. Bender, Y. Kamada, D. R. Demady, and Y. Osawa Guanabenz-mediated Inactivation and Enhanced Proteolyti |